Haiyan L. He

415 Fengyang Rd
Shanghai, 200003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Editorial: Cancer immunity and metabolic reprogramming: pioneering precision immunotherapies.

Editorial: Cancer immunity and metabolic reprogramming: pioneering precision immunotherapies.

Journal: Frontiers in immunology

Published: July 29, 2026

Nanomedicine-Based Strategies for Multiple Myeloma Therapy.

Nanomedicine-Based Strategies for Multiple Myeloma Therapy.

Journal: International journal of nanomedicine

Published: April 28, 2026

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.

Journal: Blood advances

Published: November 10, 2025

Clinical significance of cytokeratin 19 fragment in COVID-19 patients: a retrospective study.

Clinical significance of cytokeratin 19 fragment in COVID-19 patients: a retrospective study.

Journal: Frontiers in public health

Published: November 04, 2025

Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapies.

Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapies.

Journal: Cancer

Published: September 10, 2025

Clinical and genomic features of macrofocal multiple myeloma: a distinct profile.

Clinical and genomic features of macrofocal multiple myeloma: a distinct profile.

Journal: Haematologica

Published: June 23, 2025

Extracellular Ubiquitin Drives M2 Macrophage Polarization in Multiple Myeloma Through JAK1/STAT3-mediated Transcriptional Activation of CXCR4.

Extracellular Ubiquitin Drives M2 Macrophage Polarization in Multiple Myeloma Through JAK1/STAT3-mediated Transcriptional Activation of CXCR4.

Journal: Journal of cellular biochemistry

Published: May 30, 2025

Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Journal: Nature medicine

Published: April 21, 2025

GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.

GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.

Journal: The Lancet. Haematology

Published: March 15, 2025

Efficacy of synovectomy in the treatment of femoral head osteonecrosis with vascularised fibular grafting in Shanghai: a protocol for SYNERGY-VGF trial.

Efficacy of synovectomy in the treatment of femoral head osteonecrosis with vascularised fibular grafting in Shanghai: a protocol for SYNERGY-VGF trial.

Journal: BMJ open

Published: February 26, 2025

Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.

Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.

Journal: OncoTargets and therapy

Published: January 13, 2025

Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.

Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.

Journal: BMC medical genomics

Published: October 27, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026